Flag of the European Union EU Clinical Trials Register Help

Clinical trials for yondelis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: yondelis. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2018-000230-35 Sponsor Protocol Number: 014-FPO18 Start Date*: 2018-10-17
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS
    Full Title: Phase II study on the combination of trabectedin and olaparib for advanced, platinum-resistant ovarian/tubes and primary of peritoneum cancer. - TROOPS trial (TRabectedin plus Olaparib in advanced ...
    Medical condition: platinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneum
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022949-17 Sponsor Protocol Number: ET-D-009-10 Start Date*: 2010-10-20
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of las...
    Medical condition: Advanced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) FI (Completed) BE (Completed) NL (Ongoing) DK (Completed) DE (Completed) ES (Completed) AT (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2011-000137-36 Sponsor Protocol Number: TRAB1 Start Date*: 2011-07-03
    Sponsor Name:UNIVERSITA` CAMPUS BIOMEDICO
    Full Title: USE OF TRABECTEDIN IN PATIENTS WITH RELAPSED/PROGRESSION OF EPITHELIAL CARCINOMA OVARY
    Medical condition: epithelial ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061328 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004472-30 Sponsor Protocol Number: MITO23 Start Date*: 2015-12-02
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Randomized phase III trial on Trabectedin (ET-743) vs clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients
    Medical condition: recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006888 Ca ovary LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000929-40 Sponsor Protocol Number: ET743-SAR-3007 Start Date*: 2016-08-09
    Sponsor Name:Janssen Research & Development, LLC
    Full Title: A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma
    Medical condition: advanced L-sarcoma (liposarcoma or leiomyosarcoma)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024627 Liposarcoma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024189 Leiomyosarcoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004690-14 Sponsor Protocol Number: NA Start Date*: 2021-01-12
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL (REPRAB study – MITO 36)
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026311 Malignant neoplasm of ovary and other uterine adnexa LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061535 Ovarian neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004020-21 Sponsor Protocol Number: PR-Trab-PT Start Date*: 2015-04-01
    Sponsor Name:Fundación para la investigación biomédica del Hospital Clínico San Carlos
    Full Title: Reintroduction of platinum-based therapy after treatment with trabectedin in patients with relapsed ovarian cancer resistant to platinum
    Medical condition: Ovarian cancer resistant to the treatment with platinum
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002186-56 Sponsor Protocol Number: 2016/2410 Start Date*: 2016-08-18
    Sponsor Name:GUSTAVE ROUSSY
    Full Title: Randomised phase III multicentric study comparing efficacy of doxorubicin with trabectedin followed by trabectedin in non-progressive patients versus doxorubicine alone as first-line therapy in pat...
    Medical condition: Patients With Metastatic or Relapsed Unresectable Uterine or Soft Tissue Leiomyosarcoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024191 Leiomyosarcoma metastatic PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046799 Uterine leiomyosarcoma PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-000741-13 Sponsor Protocol Number: ISG-ARTICLE Start Date*: 2021-05-14
    Sponsor Name:ITALIAN SARCOMA GROUP
    Full Title: A Randomized & Observational phase II trial assessing the activity of TrabectedIn vs gemCitabine in patients with metastatic or locally advanced LEiomyosarcoma pretreated with conventional chemothe...
    Medical condition: metastatic or locally advanced Leiomyosarcoma pretreated with conventional chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005626-29 Sponsor Protocol Number: IRFMN-SARCO-7953 Start Date*: 2021-05-05
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: A phase II study on trabectedin in combination with PPARg agonist pioglitazone in patients with round cell myxoid liposarcomas or dedifferentiated G1 and G2 liposarcomas with stable disease after a...
    Medical condition: Patients with myxoid/round cell liposarcoma treated with at least 4 cycle of T alone with a stable disease at the last tumor evaluation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024628 Liposarcomas malignant HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073139 Round cell liposarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073137 Myxoid liposarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004051-78 Sponsor Protocol Number: ISG-STRADA Start Date*: 2017-05-04
    Sponsor Name:ITALIAN SARCOMA GROUP
    Full Title: Solitary fibrous tumor: phase II study on TRabectedin versus Adriamycin plus DAcarbazine in advanced patients (STRADA)
    Medical condition: Advanced Solitary Fibrous Tumor
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10041298 Soft tissue sarcomas histology unspecified HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001288-32 Sponsor Protocol Number: I3CPh1-FSM-01.11 Start Date*: 2011-04-18
    Sponsor Name:FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
    Full Title: A Pilot Study to Evaluate the Safety and Tolerability of the combination ot Trabectidin and Indole-3-Carbinol in refractory ER-positive metastatic breast cancer
    Medical condition: Refractory ER-positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000987-14 Sponsor Protocol Number: TRAMANT-01 Start Date*: 2017-10-20
    Sponsor Name:AZIENDA OSPEDALIERA PER L'EMERGENZA CANNIZZARO
    Full Title: Phase II Study: Maintenance therapy with Trabectedin after combination therapy Liposomal Doxorubicin plus Trabectedin vs Liposomal Doxorubicin plus Trabectedin in patients affected by relapsed ovar...
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033160 Ovarian epithelial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001755-31 Sponsor Protocol Number: NCT-2017-0417 Start Date*: 2018-08-31
    Sponsor Name:Ruprecht-Karls-Universität Heidelberg, Medical Faculty
    Full Title: Randomized Phase-II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
    Medical condition: Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014889-26 Sponsor Protocol Number: EORTC 62091 Start Date*: 2011-12-15
    Sponsor Name:EORTC (European Organisation for Research and Treatment of Cancer)
    Full Title: TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Ti...
    Medical condition: Histologically proven advanced and/or metastatic malignant soft tissue sarcoma intermediate/high grade, excluding the following tumor types :  Well-differentiated liposarcoma  Embryonal rhabdomyo...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) HU (Completed) DK (Completed) AT (Completed) NL (Completed) SK (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002446-47 Sponsor Protocol Number: 1320-BTG Start Date*: 2015-05-07
    Sponsor Name:European Organization for Research and Treatment of Cancer (EORTC)
    Full Title: Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group.
    Medical condition: Recurrent high-grade meningioma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027191 Meningioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) ES (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003535-38 Sponsor Protocol Number: 1447-STBSG Start Date*: 2017-07-04
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Maintenance therapy with trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma
    Medical condition: Metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) FR (Completed) CY (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001549-26 Sponsor Protocol Number: TRASTS Start Date*: 2014-11-03
    Sponsor Name:GEIS
    Full Title: Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus Radiotherapy in Soft Tissue Sarcoma patients.
    Medical condition: Soft Tissue Sarcoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-008922-55 Sponsor Protocol Number: GEIS20 Start Date*: 2009-06-04
    Sponsor Name:Grupo Español de Investigación en Sarcomas
    Full Title: ENSAYO FASE II ALEATORIZADO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO DE DOXORRUBICINA vs TRABECTEDINA Y DOXORRUBICINA EN PRIMERA LÍNEA DE PACIENTES CON SARCOMA DE PARTES BLANDAS AVANZADOS NO OPERABLES...
    Medical condition: Sarcoma de partes blandas avanzados no operables y/o metastásicos
    Disease: Version SOC Term Classification Code Term Level
    9 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001083-38 Sponsor Protocol Number: GISG-15 Start Date*: 2018-03-14
    Sponsor Name:Universitätsmedizin Greifswald
    Full Title: Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas - The NiTraSarc Phase II Trial
    Medical condition: metastatic or inoperable soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024191 Leiomyosarcoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024194 Leiomyosarcoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024629 Liposarcoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024632 Liposarcoma recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068595 Sarcoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 16:54:40 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA